1 |
Yang K. Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with review of the literature[J]. World J Gastroenterol, 2015, 21(10): 3132-3138.
|
2 |
Chen RW, Qiu MJ, Chen Y, et al. Analysis of the clinicopathological features and prognostic factors of primary hepatic neuroendocrine tumors[J]. Oncol Lett, 2018, 15(6): 8604-8610.
|
3 |
Wang L, Liu K, Lin G, et al. Primary hepatic neuroendocrine tumors: comparing CT and MRI features with pathology[J]. Cancer Imaging, 2015, 15(1): 13.
|
4 |
Yang K, Cheng YS, Yang JJ, et al. Primary hepatic neuroendocrine tumors: multi-modal imaging features with pathological correlations[J]. Cancer Imaging, 2017, 17(1): 20.
|
5 |
Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography[J]. J Clin Endocrinol Metab, 2005, 90(6): 3392-3400.
|
6 |
Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging[J]. Semin Nucl Med, 2002, 32(2): 84-91.
|
7 |
Tamm EP, Kim EE, Ng CS. Imaging of neuroendocrine tumors[J]. Hematol Oncol Clin North Am, 2007, 21(3): 409-432.
|
8 |
Ibrahim ME, Abadeer K, Zhai QJ, et al. Primary hepatic neuroendocrine tumor with unusual thyroid follicular-like morphologic characteristics[J]. Case Rep Pathol, 2017, 2017: 7931975.
|
9 |
Qiu MJ, Chen YB, Bi NR, et al. Comparative clinical analysis of gastroenteropancreatic neuroendocrine carcinomas with liver metastasis and primary hepatic neuroendocrine carcinomas[J]. Dis Markers, 2018, 2018: 9191639.
|
10 |
Pastrián LG, Ruz-Caracuel I, Gonzalez RS. Giant primary neuroendocrine neoplasms of the liver: report of 2 cases with molecular characterization[J]. Int J Surg Pathol, 2019, 27(8): 893-899.
|
11 |
Rickman DS, Beltran H, Demichelis F, et al. Biology and evolution of poorly differentiated neuroendocrine tumors[J]. Nat Med, 2017, 23(6): 1-10.
|
12 |
Patel P, Galoian K. Molecular challenges of neuroendocrine tumors[J]. Oncol Lett, 2018, 15(3): 2715-2725.
|
13 |
Uri I, Avniel-Polak S, Gross DJ, et al. Update in the therapy of advanced neuroendocrine tumors[J]. Curr Treat Options Oncol, 2017, 18(12): 72.
|
14 |
Severi S, Grassi I, Nicolini S, et al. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life[J]. Onco Targets Ther, 2017, 10: 551-557.
|
15 |
Okumura Y, Kohashi K, Wang H, et al. Combined primary hepatic neuroendocrine carcinoma and hepatocellular carcinoma with aggressive biological behavior (adverse clinical course): A case report[J]. Pathol Res Pract, 2017, 213(10): 1322-1326.
|
16 |
Zhao Z, Wang J, Ugwuowo UC, et al. Primary hepatic neuroendocrine carcinoma: report of two cases and literature review[J]. BMC Clin Pathol, 2018, 18(1): 3-10.
|
17 |
Faggiano A, Lo Calzo F, Pizza G, et al. The safety of available treatments options for neuroendocrine tumors[J]. Expert Opin Drug Saf, 2017, 16(10): 1149-1161.
|
18 |
Elizabeth M, Kathleen O, Maurine T, et al. Primary hepatic neuroendocrine carcinoma treated with doxorubicin and cyclophosphamide in a dog[J]. J Am Anim Hosp Assoc, 2019, 55(3): e55305.
|